CNB Bank’s iShares Biotechnology ETF IBB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q4
Sell
-13
Closed -$1.89K 514
2024
Q3
$1.89K Hold
13
﹤0.01% 481
2024
Q2
$1.78K Hold
13
﹤0.01% 480
2024
Q1
$1.78K Sell
13
-314
-96% -$42.9K ﹤0.01% 464
2023
Q4
$44.4K Hold
327
0.02% 261
2023
Q3
$40K Sell
327
-141
-30% -$17.9K 0.02% 262
2023
Q2
$59.4K Hold
468
0.04% 215
2023
Q1
$60.4K Sell
468
-35
-7% -$4.58K 0.04% 205
2022
Q4
$66K Hold
503
0.04% 201
2022
Q3
$59K Hold
503
0.04% 206
2022
Q2
$59K Hold
503
0.04% 203
2022
Q1
$66K Sell
503
-5
-1% -$651 0.04% 206
2021
Q4
$78K Sell
508
-41
-7% -$6.35K 0.04% 198
2021
Q3
$89K Sell
549
-213
-28% -$35.8K 0.05% 188
2021
Q2
$125K Sell
762
-614
-45% -$94.6K 0.08% 178
2021
Q1
$207K Sell
1,376
-357
-21% -$56.7K 0.14% 141
2020
Q4
$263K Buy
1,733
+602
+53% +$86K 0.2% 113
2020
Q3
$153K Buy
1,131
+609
+117% +$82.6K 0.13% 136
2020
Q2
$71K Buy
+522
New +$66.5K 0.06% 191
2019
Q4
Sell
-60
Closed -$6K 394
2019
Q3
$6K Hold
60
0.01% 343
2019
Q2
$7K Hold
60
0.01% 392
2019
Q1
$7K Hold
60
﹤0.01% 306
2018
Q4
$6K Buy
+60
New +$6.37K ﹤0.01% 291

Other funds holding IBB

CNB Bank's IBB Position: Q4 2024 in Review

CNB Bank sold out of iShares Biotechnology ETF (IBB) in Q4 2024, closing a stake of 13 shares — an estimated $1.89K sold.

CNB Bank first reported a position in IBB in Q4 2018 and held it in 22 quarters. The position peaked at $263K in Q4 2020. 874 funds tracked by Wall St. Rank hold IBB as of Q4 2024.

  • CNB Bank reported no remaining iShares Biotechnology ETF position as of Q4 2024 after selling out during the quarter.
  • CNB Bank sold 13 iShares Biotechnology ETF shares in Q4 2024, an estimated $1.89K.
  • CNB Bank first reported a position in iShares Biotechnology ETF in Q4 2018 and held it in 22 quarters.
  • CNB Bank's iShares Biotechnology ETF position peaked at $263K in Q4 2020.
  • 874 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q4 2024.

Based on CNB Bank's 13F filing for Q4 2024, filed 15 Jan 2025.